Printer Friendly

ROBERTS TO ACQUIRE QUIBRON ANTI-ASTHMA PRODUCT LINE FROM BRISTOL-MYERS SQUIBB

 EATONTOWN, N.J., Dec. 23 /PRNewswire/ -- Roberts Pharmaceutical Corporation (NASDAQ: RPCX) announced earlier today that it has entered into an agreement with Bristol-Myers Squibb (NYSE: BMY) which provides for the acquisition of all U.S. marketing rights by Roberts for Quibron(R) tablets and capsules (theophylline-quaifenesin and theophylline alone). Quibron is an important bronchodilator drug which is used for prophylaxis of asthma, a debilitating respiratory disease characterized by narrowed air passages and shortness of breath. Terms of the transaction were not disclosed; however, it was announced that the acquisition is an all-cash arrangement.
 "Quibron is a well established brand in respiratory medicine," said Dr. Robert A. Vukovich, Roberts CEO and president. "Quibron has been valuable in the management of asthma and its acquisition will serve to establish a franchise for Roberts in this important therapeutic area. Our sales force will be able to effectively call upon asthma specialists to promote Quibron in anticipation of the expected launch in 1995 of our new anti-asthma drug, Maxivent(R). The cause of asthma is poorly understood and is the subject of considerable current research to discover new cures. Asthma is the most common chronic disease in developed countries, affecting, between 5-10 percent of the Caucasian population at any one time. The highest incidence of new patients is in young children and the elderly. Asthma morbidity and mortality continue to increase despite the availability of new drug treatments. Other important respiratory medicine products currently marketed by Roberts include Nucofed(R), recently acquired from SmithKline Beecham and the Cheracol(R) family of cough/cold products," he continued.
 Roberts Pharmaceutical is an international pharmaceutical company focusing on the acquisition and development of high-potential, undervalued, late-stage development products and the acquisition of currently marketed prescription and non-prescription products. Roberts products are currently marketed in seven countries with operating subsidiary companies in the United States, Canada, and the United Kingdom. Roberts has seven drugs in late stage clinical development and currently markets over 80 different products for urological therapy, pain management, cough/cold, gastrointestinal disease, endocrine disorders and dermatological conditions.
 -0- 12/23/92
 /CONTACT: Anthony P. Maris of Roberts Pharmaceuticals, 908-389-1182/
 (RPCX BMY)


CO: Roberts Pharmaceuticals Corp.; Bristol-Myers Squibb ST: New Jersey New York IN: MTC SU: TNM

PS-WB -- NY029 -- 9629 12/23/92 14:47 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 23, 1992
Words:380
Previous Article:LYNTON GROUP, INC. ANNOUNCES MAJOR RESTRUCTURING
Next Article:INTERMAGNETICS GENERAL CORPORATION REPORTS SECOND QUARTER AND FIRST HALF RESULTS
Topics:


Related Articles
IMMUNEX ANNOUNCES PRODUCT EXCHANGE WITH BRISTOL-MYERS SQUIBB
IXSYS AND BRISTOL-MYERS SQUIBB ANNOUNCE RESEARCH AGREEMENT ON TUMOR-ASSOCIATED ANTIBODIES
STERLING WINTHROP AND ELF SANOFI ANNOUNCE JOINT DEVELOPMENT AND COMMERCIALIZATION OF TWO NEW AGENTS WITH BRISTOL-MYERS SQUIBB
BRISTOL-MYERS SQUIBB TAKES EQUITY POSITION IN IXSYS -- WILL FUND THREE-YEAR R&D PROGRAM
BRISTOL-MYERS SQUIBB, STERLING WINTHROP AND ELF SANOFI FINALIZE CARDIOVASCULAR DEVELOPMENT AGREEMENT
ENZON GRANTS BRISTOL-MYERS SQUIBB LICENSE FOR SCA(R) PROTEIN TECHNOLOGY
ROBERTS PHARMACEUTICAL CORPR?ATION ESTROGEN REPLACEMENT THERAPY MARKET IN DEAL WITH BRISTOL-MYERS SQUIBB - CANADA
ROBERTS PHARMACEUTICAL COMPLETES ACQUISITION OF ESTRACE WITH BRISTOL-MYERS SQUIBB - CANADA
BRISTOL-MYERS SQUIBB AND PRODESFARMA EXPAND MARKETING ALLIANCE FOR ANTI-INFLAMMATORY DRUG
BRISTOL-MYERS SQUIBB ANNOUNCES EXCLUSIVE COLLABORATION BETWEEN APOTHECON(R) AND INVAMED INC.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters